01—Abstract
Summary
Summary of the 8-K filed April 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Aflac reported a sharply weaker first quarter 2025 on a U.S. GAAP basis, with net earnings of just $29 milliona ($0.05 per diluted share) versus $1.9 billion ($3.25) a year earlier.
The drop was driven almost entirely by a $963 millionb net investment loss, mostly from $888 million of losses on certain derivatives and foreign currency activities, rather than by operating deterioration. Total revenues fell 37.5% to $3.4 billion for the same reason. Investors should therefore focus on the non-GAAP adjusted measures, which strip out investment gains and losses.
On an adjusted basis, the quarter was steady. Adjusted earnings were $906 millionc ($1.66 per diluted share), down 5.7% in dollars but flat per share, as a share count reduction of about 5% offset the decline. Aflac Japan's pretax adjusted earnings fell 10.9% in dollars (8.7% in yen) to $722 million, pressured by lower net earned premiums and floating-rate investment income, though the benefit ratio improved.
Aflac U.S. was resilient, with pretax adjusted earnings up 0.6% to $358 milliond, net earned premiums up 1.8%, and persistency at 79.3%. Management also flagged that the weaker yen reduced adjusted EPS by $0.01 and that variable investment income ran $27 million below long-term expectations. Capital deployment remained active.
Aflac repurchased $900 million of stock (8.5 million shares) and declared a $0.58 quarterly dividend, continuing its streak of annual increases. Book value per share rose to $48.55 on a GAAP basis, and adjusted book value excluding foreign currency remeasurement grew 2.2% to $42.61.
Adjusted ROE was 12.7% (15.6% excluding FX remeasurement). Overall, the filing shows a headline GAAP loss from non-operating items, while the core insurance franchise held up reasonably well.
02—Key points
Key Highlights
- GAAP net earnings collapsed to $29 million ($0.05 per diluted share) from $1.88 billion ($3.25) a year ago, driven by a $963 million net investment loss.
- Adjusted earnings were $906 million ($1.66 per diluted share), flat per share versus Q1 2024 despite a 5.7% decline in dollar adjusted earnings.
- Aflac Japan pretax adjusted earnings fell 10.9% to $722 million, with net earned premiums down 7.4% in dollars, partly due to internal cancer reinsurance; persistency improved to 93.8%.
- Aflac U.S. pretax adjusted earnings rose 0.6% to $358 million, net earned premiums grew 1.8%, and sales rose 3.5%, with the pretax margin at 20.8%.
- Capital returns remained strong: $900 million in buybacks and a $0.58 quarterly dividend, with 38.8 million shares remaining under authorization.
- Adjusted ROE was 12.7% (15.6% ex-FX remeasurement) and adjusted book value per share ex-remeasurement rose 2.2%, with leverage at 20.7%, within its 20-25% target range.
- Management estimates a 5-yen move versus the dollar changes underlying EPS by about $0.07, and reports $25.5 billion of unhedged USD assets in Japan.
03—Questions
Frequently Asked Questions
Why did Aflac's reported net earnings fall so sharply in Q1 2025?
The decline was driven by non-operating items rather than the core insurance business. Aflac recorded a $963 million net investment loss, mainly $888 million of losses on certain derivatives and foreign currency activities, plus $61 million from equity securities and $55 million of credit loss reserves. Those losses were only partly offset by $41 million in gains from sales and redemptions. Because these items are volatile and largely outside management's control, management excludes them from adjusted earnings.
Is Aflac's underlying profitability still stable?
On an adjusted basis, yes. Adjusted EPS was flat at $1.66, and adjusted ROE was 12.7%, or 15.6% excluding FX remeasurement. Aflac U.S. margins held near 21%, and Japan's pretax margin was 31.8%, though down from 32.8% a year earlier. Japan's results were pressured by lower premiums and investment income, while U.S. results were supported by premium growth and expense discipline.
How much did the weaker yen affect results, and how exposed is Aflac?
The weaker yen reduced adjusted EPS by about $0.01 in the quarter, with the average yen/dollar rate at 152.40 versus 148.67 a year earlier. Management estimates that each 5-yen move in the yen/dollar rate changes underlying EPS by roughly $0.07. Aflac partly hedges this exposure through roughly 59% yen-denominated debt, put options with $24.2 billion notional, and forward contracts, and it holds $25.5 billion of unhedged USD assets in Japan.
Is Aflac continuing to return capital to shareholders?
Yes. Aflac repurchased $900 million of stock (8.5 million shares) in Q1 2025 and declared a $0.58 quarterly dividend, payable June 2, 2025. The dividend was 16% higher than a year earlier. Management said it remains committed to extending its streak of annual dividend increases, which reached 42 consecutive years in 2024. The company had 38.8 million shares remaining under its repurchase authorization at quarter-end.
What are the main risks or items to watch going forward?
Investors should watch Aflac Japan's premium trend, since net earned premiums fell 5% and underlying premiums declined 1.4%, partly reflecting the cancer reinsurance transaction and paid-up policies. They should also monitor variable investment income, which ran $27 million below expectations, and investment income pressure from lower floating-rate returns. Currency and derivative-related investment volatility remain a major source of GAAP earnings swings. In the U.S., the expense ratio was 37.6% but growth initiatives added about 50 basis points to it, and CECL reserves on commercial real estate continued to rise.
04—Continue